首页> 中文期刊> 《中国民康医学》 >利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的临床疗效

利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的临床疗效

         

摘要

目的::对比分析利培酮单用与利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的治疗效果。方法:将68例甲基苯丙胺所致精神障碍患者的临床资料,采用数字单双号的模式随机分为对照组(利培酮)与治疗组(利培酮合并帕罗西汀),每组各34例。结果:对照组患者的总有效率为82.35%,治疗组患者的总有效率为94.12%,治疗组明显高于对照组,(P<0.05)差异具有统计学意义;两组患者不良反应的对比不具有统计学意义(P>0.05)。结论:针对甲基苯丙胺所致精神障碍患者,采用利培酮合并帕罗西汀进行治疗能够显著改善患者的精神病性状态和抑郁、焦虑情绪,临床疗效明显,值得临床推广应用。%Objective: To comparatively analyze effects of Risperidone alone and Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients. Methods: A retrospective analysis of clinical data of 68 cases with methamphetamine-induced mental disorder was done by using digital odd and even numbers modes, and these cases were randomly di-vided into control group ( Risperidone) and treatment group ( Risperidone merger Paroxetine) , 34 cases in each group. Results:The total effective rates of control group and treatment group were 82. 35% and 94. 12%, and the difference was statistically significant (P<0. 05). The adverse reactions of the two groups were not statistically significant (P>0. 05). Conclusions:For the methamphetamine-induced mental disorder patients, Paroxetine combined with Risperidone can significantly improve the patient's mental state and de-pression and anxiety emotions with a significant clinical efficacy, and is worthy of clinical application and promotion.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号